Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls.
We measured the concentration of C9 in the CSF and plasma of 93 consecutive patients referred for CSF examination in an outpatient multispecialty clinic. We noted no differences in CSF C9 or C9 index between patients with multiple sclerosis and neurologic controls.